Indrayani Biotech (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Indrayani Biotech Limited |
|||
|
Price: ₹35.17 | ||
| 52 Week Low: ₹34.02 52 Week High: ₹89.40 |
|||
| Market Capital: 15.43 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Indrayani Biotech Share Price Target For 2024
- 1.1.1: Indrayani Biotech Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Indrayani Biotech Share Price Target For 2025
- 1.2.1: Indrayani Biotech Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Indrayani Biotech Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Indrayani Biotech Financial Performance
- 3.0.1: Is Indrayani Biotech A Good Buy For Long Term?
To predict the Indrayani Biotech's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Indrayani Biotech Share Price Target For 2024
The line chart displays the monthly closing prices of Indrayani Biotech with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Indrayani Biotech shares in 2024, see the table below.
Indrayani Biotech Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 36.7 (+4.34%) | Price Action: 29 Nov 2024 Low |
| 2024 Target 2 | 36.26 (+3.09%) | Price Action: 13 Dec 2024 Low |
| 2024 Target 1 | 35.9 (+2.06%) | Price Action: 17 Dec 2024 Low |
| Current Price | 35.17 | Indrayani Biotech's share price as of 26 Dec 2024 |
| Stop Loss 1 | 34.87 (-0.86%) | Price Action: Chart |
| Stop Loss 2 | 34.08 (-3.1%) | Fibonacci Retracement Level 98.60% |
| Stop Loss 3 | 33.45 (-4.9%) | Price Action: Apr 2022 High |
Short-Term Technical Outlook
Current Technical Position: Indrayani Biotech is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹36.63 serves as the nearest technical reference point.
Historical Returns: 3-month: -13.48% | 6-month: -42.8% | 1-year: -44.32%
Indrayani Biotech Share Price Target For 2025
The line chart displays the monthly closing prices of Indrayani Biotech with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Indrayani Biotech shares in 2025, see the table below.
Indrayani Biotech Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 70.65 (+100.88%) | Price Action: 11 Jul 2023 High |
| 2025 Target 2 | 69.55 (+97.75%) | Price Action: 26 Feb 2024 Low |
| 2025 Target 1 | 68.84 (+95.73%) | Price Action: 16 Feb 2024 Low |
| Current Price | 35.17 | Indrayani Biotech's share price as of 26 Dec 2024 |
| Stop Loss 1 | 26.42 (-24.88%) | Price Action: Chart |
| Stop Loss 2 | 26.16 (-25.62%) | Price Action: Chart |
| Stop Loss 3 | 25.69 (-26.96%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Indrayani Biotech is currently trading near its 52-week low of ₹34.02, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -44.32% | 3-year: +31.48% | 5-year: +435.31%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Indrayani Biotech Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹35.17 | ||
| 2024 | ₹47.39 | +34.74% | ₹48.10 |
| 2025 | ₹26.55 | -43.97% | ₹47.62 |
| 2026 | ₹29.08 | +9.52% | ₹37.25 |
| 2027 | ₹26.51 | -8.83% | ₹34.97 |
| 2028 | ₹39.05 | +47.3% | ₹40.74 |
| 2029 | ₹42.44 | +8.68% | ₹43.08 |
| 2030 | ₹32.49 | -23.44% | ₹44.46 |
| 2031 | ₹69.71 | +114.55% | ₹73.67 |
| 2032 | ₹79.69 | +14.31% | ₹97.82 |
| 2033 | ₹101.83 | +27.78% | ₹103.36 |
| 2034 | ₹90.58 | -11.04% | ₹97.23 |
| 2035 | ₹82.97 | -8.4% | ₹93.85 |
| 2036 | ₹81.43 | -1.85% | ₹97.39 |
| 2037 | ₹92.65 | +13.77% | ₹97.49 |
| 2038 | ₹117.88 | +27.23% | ₹119.65 |
| 2039 | ₹95.89 | -18.65% | ₹97.33 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Indrayani Biotech Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 15.43 Crore | Market valuation of Indrayani Biotech's shares. |
| Revenue (TTM) | 166.22 Crore | Total revenue generated by Indrayani Biotech over the past twelve months. |
| Net Income (TTM) | +6.36 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +12.54% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +41.56% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-28.96% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
1.47 | Company's total debt divided by total shareholder equity. |
| Total Debt | 112.52 Crore | Sum of Indrayani Biotech's current & long-term financial obligations. |
| Total Cash | 58.21 Lakh | Total amount of liquid funds available to Indrayani Biotech. |
Is Indrayani Biotech A Good Buy For Long Term?
Indrayani Biotech, a small-cap stock with a market capitalization of ₹15.43 crore, presents a mixed picture for long-term investors. While it boasts impressive revenue (₹166.22 crore TTM) and a high profit margin (41.56%), its substantial debt (₹112.52 crore Q1 2024-25) and extremely low cash balance (₹58.21 lakh) raise serious concerns. Negative returns over the past year (-35.20%) and YTD (-40.34%) further fuel caution. Although past 3-year and 5-year returns are positive, the current financial health necessitates a thorough due diligence before considering a long-term investment. It's currently a not a good buy.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
